AKYA:NSD-Akoya Biosciences Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 11.80

Change

-0.51 (-4.14)%

Market Cap

USD 0.45B

Volume

0.07M

Avg Analyst Target

USD 17.71 (+50.12%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AKYA Stock Forecast & Price:
Based on the Akoya Biosciences Inc stock forecasts from 4 analysts, the average analyst target price for Akoya Biosciences Inc is USD 17.71 over the next 12 months. Akoya Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akoya Biosciences Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Akoya Biosciences Inc’s stock price was USD 11.80. Akoya Biosciences Inc’s stock price has changed by -9.09% over the past week, -9.30% over the past month and -14.12% over the last year.

About Akoya Biosciences Inc (AKYA:NSD)

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact be ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

+1.65 (+0.62%)

USD96.21B 72.99 46.05
HOLX Hologic Inc

-0.42 (-0.57%)

USD18.81B 15.12 9.17
RGEN Repligen Corporation

+1.20 (+0.71%)

USD10.33B 57.96 40.09
NVCR Novocure Ltd

+1.87 (+2.54%)

USD8.40B 1,480.87 -125.83
MASI Masimo Corporation

+0.74 (+0.53%)

USD7.65B 48.50 28.74
XRAY Dentsply Sirona Inc

-0.35 (-1.16%)

USD6.81B 19.92 -16.85
QDEL Quidel Corporation

+0.42 (+0.46%)

USD6.23B 6.02 6.81
AZTA Azenta Inc

+0.18 (+0.31%)

USD4.51B 2.03 64.48
MMSI Merit Medical Systems Inc

+0.30 (+0.42%)

USD4.16B 70.23 25.73
ICUI ICU Medical Inc

-0.66 (-0.43%)

USD3.87B 329.47 29.26

ETFs Containing AKYA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.93% 78% C+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.93% 78% C+ 50% F
Trailing 12 Months  
Capital Gain -13.87% 79% C+ 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.87% 79% C+ 59% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.83% 27% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.83% 27% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 17.70% 95% A 73% C
Risk Adjusted Return -55.56% 16% F 22% F
Market Capitalization 0.45B 60% D- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.34 21% F 14% F
Price / Cash Flow Ratio -12.42 79% C+ 73% C
EV/EBITDA -7.98 78% C+ 80% B-
Management Effectiveness  
Return on Equity -65.36% 32% F 24% F
Return on Invested Capital -37.85% 30% F 28% F
Return on Assets -21.81% 36% F 24% F
Debt to Equity Ratio 26.76% 39% F 52% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 19.35 5% F 3% F
Short Percent 8.19% 17% F 19% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector